These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35973926)

  • 1. Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer.
    Simons MJHG; Uyl-de Groot CA; Retèl VP; Mankor JM; Ramaekers BLT; Joore MA; van Harten WH
    Value Health; 2023 Jan; 26(1):71-80. PubMed ID: 35973926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer.
    Simons MJHG; Retèl VP; Ramaekers BLT; Butter R; Mankor JM; Paats MS; Aerts JGJV; Mfumbilwa ZA; Roepman P; Coupé VMH; Uyl-de Groot CA; van Harten WH; Joore MA
    Pharmacoeconomics; 2021 Dec; 39(12):1429-1442. PubMed ID: 34405371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy.
    Mfumbilwa ZA; Simons MJHG; Ramaekers B; Retèl VP; Mankor JM; Groen HJM; Aerts JGJV; Joore M; Wilschut JA; Coupé VMH
    Pharmacoeconomics; 2024 Apr; 42(4):419-434. PubMed ID: 38194023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole genome sequencing in oncology: using scenario drafting to explore future developments.
    van de Ven M; Simons MJHG; Koffijberg H; Joore MA; IJzerman MJ; Retèl VP; van Harten WH
    BMC Cancer; 2021 May; 21(1):488. PubMed ID: 33933021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing.
    Doble B; John T; Thomas D; Fellowes A; Fox S; Lorgelly P
    Lung Cancer; 2017 May; 107():22-35. PubMed ID: 27316470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
    Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
    Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
    Guan H; Liu G; Xie F; Sheng Y; Shi L
    Clin Ther; 2019 Nov; 41(11):2308-2320.e11. PubMed ID: 31607559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 11. Scenario drafting to anticipate future developments in technology assessment.
    Retèl VP; Joore MA; Linn SC; Rutgers EJ; van Harten WH
    BMC Res Notes; 2012 Aug; 5():442. PubMed ID: 22894140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
    Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
    Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer.
    van de Ven M; IJzerman M; Retèl V; van Harten W; Koffijberg H
    BMC Med Res Methodol; 2022 Mar; 22(1):83. PubMed ID: 35350994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scenario analysis and multi-criteria decision analysis to explore alternative reimbursement pathways for whole genome sequencing for blood cancer patients.
    Vu M; Degeling K; Westerman D; IJzerman MJ
    J Cancer Policy; 2024 Sep; 41():100501. PubMed ID: 39142605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations.
    Westerink L; Nicolai JLJ; Samuelsen C; Smit HJM; Postmus PE; Griebsch I; Postma MJ
    Eur J Health Econ; 2020 Aug; 21(6):931-943. PubMed ID: 32328874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer.
    Lin S; Luo S; Zhong L; Lai S; Zeng D; Rao X; Huang P; Weng X
    Int J Clin Pharm; 2020 Aug; 42(4):1175-1183. PubMed ID: 32524512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE).
    Samsom KG; Bosch LJW; Schipper LJ; Roepman P; de Bruijn E; Hoes LR; Riethorst I; Schoenmaker L; van der Kolk LE; Retèl VP; Frederix GWJ; Buffart TE; van der Hoeven JJM; Voest EE; Cuppen E; Monkhorst K; Meijer GA
    BMC Med Genomics; 2020 Nov; 13(1):169. PubMed ID: 33167975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer.
    Roth JA; Billings P; Ramsey SD; Dumanois R; Carlson JJ
    Oncologist; 2014 May; 19(5):466-76. PubMed ID: 24710309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis.
    Brazzelli M; Aucott L; Aceves-Martins M; Robertson C; Jacobsen E; Imamura M; Poobalan A; Manson P; Scotland G; Kaye C; Sawhney S; Boyers D
    Health Technol Assess; 2022 Jan; 26(7):1-286. PubMed ID: 35115079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.